Glucosamine Use Tied to 25% Alzheimer’s Progression
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Glucosamine users with mild cognitive impairment had a 25% higher likelihood of progressing to dementia than non‑users after adjusting for age, sex and demographics.
- UF Health electronic health records from 2012‑2024 were AI‑analyzed, identifying 2,750 MCI patients and 1,896 ADRD patients who reported glucosamine use, about 8% of each group.
- Ramon Sun said the overactive hyperglycosylation pathway in Alzheimer’s brains could be a new therapeutic target.
- Matt Gentry cautioned that the association is provocative but not proof of causality, urging further clinical trials.
- Glucosamine increased protein sugar‑tagging and impaired social memory in genetically modified mice, while reducing the tagging improved performance.
- UF Neuromedicine Brain and Tissue Bank samples showed substantially higher protein sugar‑attachment in Alzheimer’s brains versus healthy controls.
- Glucosamine use was associated with a 25% higher mortality risk among patients already diagnosed with Alzheimer’s, a pattern not seen in MCI patients.
Why it matters: The study suggests that glucosamine could worsen disease trajectory, implying that patients with MCI or Alzheimer’s may need to reconsider its use, and clinicians may need to weigh these risks against joint‑health benefits. The findings also highlight a metabolic pathway that could become a therapeutic target, potentially shifting research focus and drug development priorities.
Ask SkimNews
